Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).

doi:10.1038/srep16331

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).

Scientific reports - 17 Nov 2015

Ganzinelli Monica, Rulli Eliana, Caiola Elisa, Garassino Marina Chiara, Broggini Massimo, Copreni Elena, Piva Sheila, Longo Flavia, Labianca Roberto, Bareggi Claudia, Fabbri Maria Agnese, Martelli Olga, Fagnani Daniele, Locatelli Maria Cristina, Bertolini Alessandro, Valmadre Giuseppe, Pavese Ida, Calcagno Anna, Sarobba Maria Giuseppa, Marabese Mirko

Abstract excerpt

MicroRNAs were described to target mRNA and regulate the transcription of genes involved in processes de-regulated in tumorigenesis, such as proliferation, differentiation and survival. In particular, the miRNA let-7 has been suggested to regulate the expression of the KRAS gene, a common mutated gene in non-small cell lung cancer (NSCLC), through a let-7 complementary site (LCS) in 3'UTR of KRAS mRNA. We have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3' Untranslated Regions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Docetaxel

Share to Erlotinib Hydrochloride

Share to Kaplan-Meier Estimate

Share to Proportional Hazards Models

Share to ras Proteins

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 26573509
DOI: 10.1038/srep16331
PMCID: PMC4648064

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR).PMID 26573509Read ↗

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.Semantic proximity Read ↗

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).Semantic proximity Read ↗

The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.Semantic proximity Read ↗

Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patientsSemantic proximity Read ↗

A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.Semantic proximity Read ↗

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.Semantic proximity Read ↗

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.Semantic proximity Read ↗

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.Semantic proximity Read ↗

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.Semantic proximity Read ↗

KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer.Semantic proximity Read ↗

KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.Semantic proximity Read ↗

Evaluation of the simultaneous effects of KRAS G12V and LCS6 alterations on the behavior of head and neck squamous cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.